Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS-553 in Relapsed or Refractory CLL/SLL (Phase I/II)
CTR20220188Phase 2Terminated
- Sponsor
- Mingsairuilin Pharmaceutical
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MS-553 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Mingsairuilin Pharmaceutical. Started Feb 2022; status: terminated.
02
Drugs
MS-553
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20220188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220188.